NantKwest Announces Promising First in Human Clinical Results of 300 Doses of CD16 Targeted, Off-the-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy

Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination...